New hope for women battling aggressive ovarian cancer
NCT ID NCT06855069
Summary
This study is testing whether a new drug called HS-20089 works better than standard chemotherapy for women whose ovarian cancer has returned and stopped responding to platinum-based drugs. About 468 women with recurrent ovarian, fallopian tube, or primary peritoneal cancer will be randomly assigned to receive either the new drug or their doctor's choice of chemotherapy. The main goal is to see if HS-20089 can keep the cancer from growing for longer than current treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Conditions
Explore the condition pages connected to this study.